Difference between revisions of "Part:BBa K3781212"

 
(2 intermediate revisions by the same user not shown)
Line 36: Line 36:
  
  
This L1 construct has been <b>successfully transfected</b> into Leishmania and resulting recombinant protein expression was observed after purification and immunoblotting, see <i>Figure 2</i>. For more detailed elaboration on the <b>interpretation</b> of this western blot, please refer to the <html><a href="https://parts.igem.org/Part:BBa_K3781019"><b>L0_GST_B5</a></b></html> parts page.
+
This L1 composite part has been <b>successfully transfected</b> into <i>Leishmania</i> and recombinant protein expression could be observed via <b>immunostaining</b> on <b>western blot</b>, see <i>Figure 2</i>.
  
  
 
<div><ul>
 
<div><ul>
<li style="display: inline-block;"> [[File:T--TU Kaiserslautern--Blot L1 sAP RBD mVenus GST.png|thumb|none|500px|<b>Figure 2</b> &#124; <b>Immunoblot</b> &#124; <html><a href="https://parts.igem.org/Part:BBa_K378212">L1_sAP_RBD_mVenus_GST</a></html> &#124; after GST-purification<br>
+
<li style="display: inline-block;"> [[File:T--TU Kaiserslautern--Blot B5 mVenus.png|thumb|none|500px|<b>Figure 2</b> &#124; <b>Immunoblot</b> of L1 transfected <i>Leishmania</i> cell cultures &#124; stained against <b>RBD</b><br>
 +
<b>1</b> &#124; <html><a href="https://parts.igem.org/Part:BBa_K3781210">L1_sAP_RBD_mVenus</a></html> &#124; 52.1 kDa<br>
 +
<b>2</b> &#124; <b>L1_sAP_RBD_mVenus_GST</b> &#124; 78.8 kDa<br>
 +
<b>3</b> &#124; <html><a href="https://parts.igem.org/Part:BBa_K3781201">L1_3xHA_RBD_mVenus</a></html> &#124; 55.9 kDa<br>
 +
<b>4</b> &#124; <html><a href="https://parts.igem.org/Part:BBa_K3781206">L1_sAP_RBD_HA8His</a></html> &#124; 28 kDa<br>
 +
<b>n.c.</b> &#124; negative control &#124; <i>Leishmania</i> culture<br> transfected with empty L1 expression vector<br>
 +
<b>p.c.</b> &#124; RBD-GFP &#124; 52 kDa<br>
 +
<b>L</b> &#124; Thermofischer PageRuler Protein Ladder [kDa]<br>
 +
1. AB &#124; ms <b>anti-RBD</b> &#124; 1:2,000<br>
 +
2. AB &#124; rb <b>anti-ms HRP</b> &#124; 1:10,000<br> ]] </li>
 +
</ul></div>
 +
 
 +
 
 +
After expression analysis, this construct was <b>GST-purified</b> and via <b>immunoblotting</b>, purified recombinant protein could be <b>verified</b>, see <i>Figure 3</i>. For more detailed elaboration on the <b>interpretation</b> of this western blot, please refer to the <html><a href="https://parts.igem.org/Part:BBa_K3781019"><b>L0_GST_B5</a></b></html> parts page.
 +
 
 +
 
 +
<div><ul>
 +
<li style="display: inline-block;"> [[File:T--TU Kaiserslautern--Blot L1 sAP RBD mVenus GST.png|thumb|none|500px|<b>Figure 3</b> &#124; <b>Immunoblot</b> &#124; <html><a href="https://parts.igem.org/Part:BBa_K378212">L1_sAP_RBD_mVenus_GST</a></html> &#124; after GST-purification<br>
 
1. AB &#124; <b>ms anti-GST</b><br>
 
1. AB &#124; <b>ms anti-GST</b><br>
 
2. AB &#124; <b>rb anti-ms HRP</b><br>  
 
2. AB &#124; <b>rb anti-ms HRP</b><br>  

Latest revision as of 03:54, 22 October 2021


L1_sAP_RBD_mVenus_GST, MocloMania Composite

MocloMania

This composite part contains the sAP secretion signal, a coding sequence for the SARS-CoV-2 receptor binding domain, a fluorescent mVenus tag as well as a C-terminal GST-tag fused with a TEV protease recognition motif. The invidual basic parts are joined together by the MoClo connectors for B2/B3, B3/B4 and B4/B5.

L1_sAP_RBD_mVenus_GST allows for transgenic expression of the SARS-CoV2 receptor binding domain in Leishmania tarentolae and secretion of the fusion protein into the culture medium. By concentrating the culture medium and running it over a gluthatione agarose column, the GST-tagged fusion protein should be able to be purified. Elution under native conditions allows for subsequent activity and functionality testing of purified RBD via ACE2 binding assay. Here, the fused mVenus can facilitate protein detection via fluorescence microscopy.


level 1

size 2157 bp

antibiotic resistance in E. Coli ampicillin

plasmid backbone weird_plex

Data

We were able to successfully assemble this composite part into our L1 expression vector weird_plex and confirm the integrity of the resulting L1 construct via restriction digest and gel electrophoresis, see Figure 1. Along with subsequent sequencing, this verified the correct adaptation of the underlying basic parts to the MoClo cloning standard.



This L1 composite part has been successfully transfected into Leishmania and recombinant protein expression could be observed via immunostaining on western blot, see Figure 2.


  • Figure 2 | Immunoblot of L1 transfected Leishmania cell cultures | stained against RBD
    1 | L1_sAP_RBD_mVenus | 52.1 kDa
    2 | L1_sAP_RBD_mVenus_GST | 78.8 kDa
    3 | L1_3xHA_RBD_mVenus | 55.9 kDa
    4 | L1_sAP_RBD_HA8His | 28 kDa
    n.c. | negative control | Leishmania culture
    transfected with empty L1 expression vector
    p.c. | RBD-GFP | 52 kDa
    L | Thermofischer PageRuler Protein Ladder [kDa]
    1. AB | ms anti-RBD | 1:2,000
    2. AB | rb anti-ms HRP | 1:10,000


After expression analysis, this construct was GST-purified and via immunoblotting, purified recombinant protein could be verified, see Figure 3. For more detailed elaboration on the interpretation of this western blot, please refer to the L0_GST_B5 parts page.


  • Figure 3 | Immunoblot | L1_sAP_RBD_mVenus_GST | after GST-purification
    1. AB | ms anti-GST
    2. AB | rb anti-ms HRP
    I Input  |  FT Flowthrough  |  W Wash  |  E Eluate  |  E.T Eluate, TCA precipitated
    L | Thermo Scientific PageRuler Protein Ladder [kDa]


The MocloMania collection

This L1 construct was assembled using basic parts from the MocloMania collection, the very first collection of genetic parts specifically designed and optimized for Modular Cloning assembly and recombinant protein expression in the protozoan parasite Leishmania tarentolae.

Are you trying to express complexly glycosylated proteins? Large antibody side chains? Human proteins that require accurate post-translational modification? Then Leishmania might be just the right organism for you! Leishmania tarentolae’s glycosylation patterns resemble those of human cells more closely than any other microbial expression host, while still delivering all the benefits of microbial production systems like easy transfection and cultivation.[1] So instead of relying on mammalian cell lines, try considering Leishmania as your new expression host of choice!

Our MocloMania collection will allow you to easily modify your protein of choice and make it suitable for downstream detection and purification procedures - all thanks to the help of Modular Cloning. This cloning system was first established by Weber et al. in 2011 and relies on the ability of type IIS restriction enzymes to cut DNA outside of their recognition sequence, hereby generating four nucleotide overhangs.[2] Every basic part in our collection is equipped with a specified set of overhangs that assign it to its designated position within the reading frame. These so-called cloning positions are labelled B2-B5 from upstream to downstream. By filling all positions with the basic parts of your choice, you can easily generate variable genetic constructs that code for the fusion protein of your desire.

We furthermore provide a specifically domesticated Leishmania expression vector, named weird_plex, which will package your fusion construct into a functional transcriptional unit that is optimized for high expression in Leishmania.

The best part? Because of the type IIS restriction properties and the specifity of the generated overhangs, restriction and ligation of your construct can all happen simultaneously in a simple one-step, one-pot reaction. This will safe you a lot of time and frustration in your cloning endeavours!

Do we have your attention? In the table below you can find some basic information on how our cloning system, along with most other MoClo systems, is set up. Please feel free to check out our wiki to find more information on Leishmania and Modular Cloning as well as to understand how the part that you are looking at integrates into our part collection. See you there!


MOCLO | Important nomenclature and parameters
Level What does this level contain? antibiotic resistance Enzyme used for ligation
L0 The foundation to every MoClo construct which are basic genetic units, such as coding sequences, promoters, terminators spectinomycin BbsI
L1 Several L0 parts assembled into a functional transcriptional unit, e.g. consisting of promoter, coding region and terminator ampicillin BsaI
L2 Multiple transcriptional units added into one multi-gene construct, e.g. a protein of interest fused to a selection marker kanamycin BbsI

Sequence and Features


Assembly Compatibility:
  • 10
    INCOMPATIBLE WITH RFC[10]
    Illegal PstI site found at 598
    Illegal PstI site found at 955
    Illegal PstI site found at 2101
  • 12
    INCOMPATIBLE WITH RFC[12]
    Illegal PstI site found at 598
    Illegal PstI site found at 955
    Illegal PstI site found at 2101
  • 21
    INCOMPATIBLE WITH RFC[21]
    Illegal BglII site found at 536
    Illegal XhoI site found at 6
  • 23
    INCOMPATIBLE WITH RFC[23]
    Illegal PstI site found at 598
    Illegal PstI site found at 955
    Illegal PstI site found at 2101
  • 25
    INCOMPATIBLE WITH RFC[25]
    Illegal PstI site found at 598
    Illegal PstI site found at 955
    Illegal PstI site found at 2101
    Illegal NgoMIV site found at 684
    Illegal NgoMIV site found at 1432
  • 1000
    INCOMPATIBLE WITH RFC[1000]
    Illegal SapI.rc site found at 708
    Illegal SapI.rc site found at 2073
    Illegal SapI.rc site found at 2145


  1. Langer T, Corvey C, Kroll K, Boscheinen O, Wendrich T, Dittrich W. Expression and purification of the extracellular domains of human glycoprotein VI (GPVI) and the receptor for advanced glycation end products (RAGE) from Rattus norvegicus in Leishmania tarentolae. Prep Biochem Biotechnol. 2017 Nov 26;47(10):1008-1015. doi: 10.1080/10826068.2017.1365252. Epub 2017 Aug 31. PMID: 28857681.
  2. Weber E, Engler C, Gruetzner R, Werner S, Marillonnet S (2011) A Modular Cloning System for Standardized Assembly of Multigene Constructs. PLoS ONE 6(2): e16765. https://doi.org/10.1371/journal.pone.0016765